Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Accenture
Baxter
QuintilesIMS
Farmers Insurance
Chubb
Johnson and Johnson
Covington
Moodys
Federal Trade Commission

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,439,906

« Back to Dashboard

Which drugs does patent 9,439,906 protect, and when does it expire?


Patent 9,439,906 protects INVEGA SUSTENNA and is included in one NDA.

This patent has twenty-one patent family members in sixteen countries.

Summary for Patent: 9,439,906

Title:Dosing regimen associated with long acting injectable paliperidone esters
Abstract: The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.
Inventor(s): Vermeulen; An (Beerse, BE), Wouters; Alfons (Beerse, BE)
Assignee: Janssen Pharmaceutica NV (BE)
Application Number:12/337,144
Patent Claim Types:
see list of patent claims
Use; Formulation; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-001Jul 31, 2009RXYesNo► Subscribe► Subscribe TREATMENT OF SCHIZOPHRENIA
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-001Jul 31, 2009RXYesNo► Subscribe► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-002Jul 31, 2009RXYesNo► Subscribe► Subscribe TREATMENT OF SCHIZOPHRENIA
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-002Jul 31, 2009RXYesNo► Subscribe► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-003Jul 31, 2009RXYesNo► Subscribe► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-003Jul 31, 2009RXYesNo► Subscribe► Subscribe TREATMENT OF SCHIZOPHRENIA
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-004Jul 31, 2009RXYesYes► Subscribe► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-004Jul 31, 2009RXYesYes► Subscribe► Subscribe TREATMENT OF SCHIZOPHRENIA
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-005Jul 31, 2009RXYesNo► Subscribe► Subscribe TREATMENT OF SCHIZOPHRENIA
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-005Jul 31, 2009RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,439,906

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2008340101► Subscribe
Australia2015200801► Subscribe
BrazilPI0821408► Subscribe
Canada2655335► Subscribe
China101932327► Subscribe
China105560176► Subscribe
Colombia6300949► Subscribe
Eurasian Patent Organization020697► Subscribe
Eurasian Patent Organization201070757► Subscribe
EcuadorSP10010289► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Daiichi Sankyo
Baxter
Chubb
Argus Health
US Army
Cipla
McKesson
Colorcon
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot